Centering discussion on the JAK inhibitor pacritinib, expert panelists review data from recent clinical trials and consider how they inform real-world use of this agent.
Expert panelists consider key molecular markers that guide the classification and management of myelofibrosis, along with other important subsets of disease.
Bengaluru (Karnataka) [India], February 3 (ANI/NewsVoir): With a vision to strengthen its presence in cancer care solutions in Karnataka region, Dr Devi Shetty, Chairman & Executive Director, Narayana Health and Kiran Mazumdar Shaw, Executive Chairperson - Biocon Limited and Biocon Biologics Limited today inaugurated a new Bone Marrow Transplant (BMT) Unit at Mazumdar Shaw Medical Centre, Narayana Health City. The event was also graced by Dr Emmanuel Rupert, Managing Director and Group CEO, Narayana Health and Dr Sharat Damodar, Chairman - Oncology Services & Clinical Director - MSMC, Narayana Health. With the launch, BMT Unit has strengthened its capacity to 34 beds by adding 10 new beds. Furthermore, the inauguration was attended by 35 cancer survivors to raise awareness about cancer, importance of early detection and latest treatment modalities. The new unit aims to offer patients from Bengaluru, Karnataka state and nearby areas an easy access to qualified international stan